Under construction – not a live service
Sign in
Taking people in ItalyNo phase

Measuring RNA Patterns in Heart Failure and Aortic Stenosis Patients

Measures RNA signals in tissue and blood of people with heart failure or aortic stenosis.

Plain-language title generated from the registry record
Registry title: Heart Failure and Aortic Stenosis Transcriptome

Key facts

Where
Milan and San Donato Milanese, ItalySee the 2 sites

AI summary: who the study is looking for

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults aged 40 to 75 with heart failure (not end-stage or end-stage) or aortic stenosis who are having heart surgery. Blood and tissue samples will be studied.

Age
40 to 75 years
Sex
All sexes
Disease stage
Non end-stage heart failure with Ejection Fraction (EF) <40%, End Systolic Volume Index (ESVI) >35 ml/m2 and a previous transmural anterior heart attack, having left ventricle restoration surgery. Or end-stage heart failure with EF <25% and ESVI ≥60 ml/m2, having left ventricle assisted device (LVAD) surgery. Or aortic stenosis with pressure difference >40 mmHg and septal diameter ≥1.3 cm (0.5 in), having aortic valve replacement.
Earlier treatment
Not asked for. Chemotherapy or radiotherapy, and prolonged use of corticosteroids, are reasons not to join.

Main reasons for not taking part

  • Pregnancy
  • Cancer (neoplasms)
  • Infections, or HIV, hepatitis B (not from vaccination) or hepatitis C
  • Other genetic diseases or collagen diseases
  • Coronary artery disease (aortic stenosis group)

Read by machine on 12 November 2026.

Could this be for you?

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 40 and 75 years old?

Source: NCT03268135, who can take part

Where in Italy

  • Ospedale San RaffaeleMilan, ItalyContact: Michele De Bonis, MD, PhDTaking people
  • IRCCS Policlinico San DonatoSan Donato Milanese, ItalyContact: FABIO MARTELLI, PhDTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Trial details

Who runs it
IRCCS Policlinico S. Donato
Trial code
NCT03268135
Record updated
4 November 2026
Original description
This study is aimed to investigate the global transcriptome in order to determine the expression profile of messenger RNAs (mRNAs), as well as long noncoding- (lncRNAs) and micro noncoding-RNAs (miRNAs) in heart failure (HF) and in aortic stenosis (AS). The aim is to clarify their role in cardiac disease pathogenesis, as well as their potential as biomarkers. To this purpose, both tissue and blood specimens will be collected and patients will be compared to individuals not affected by cardiovascular diseases.Read full original descriptionShow less

Study of the Transcriptomic Alterations in Heart Failure and Aortic Stenosis

This study is aimed to investigate the global transcriptome in order to determine the expression profile of messenger RNAs (mRNAs), as well as long noncoding- (lncRNAs) and micro noncoding-RNAs (miRNAs) in heart failure (HF) and in aortic stenosis (AS). The aim is to clarify their role in cardiac disease pathogenesis, as well as their potential as biomarkers. To this purpose, both tissue and blood specimens will be collected and patients will be compared to individuals not affected by cardiovascular diseases.

Inclusion: Non end-stage heart failure; left ventricle restoration surgery (SVR); End Systolic Volume Index (ESVI) >35 ml/m2; Ejection Fraction (EF)<40%; previous transmural anterior myocardial infarction (MI); age: 40-75; End-stage heart failure; left ventricle assisted device (LVAD) surgery; age: 40-75; Ejection Fraction (EF) <25%; End Systolic Volume Index (ESVI)≥60 ml/m2; Aortic Stenosis; aortic valve replacement; intracardial pressure difference >40 mmHg; septal diameter ≥1.3 cm.

Exclusion: End-stage heart failure; EF>25%; Time from MI unknown; Pregnancy; Other genetic diseases; Neoplasms; Collagenopathies; Chemo/radiotherapy; Prolonged use of corticosteroids; Infections; Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV) (not vaccination) and Hepatitis C Virus (HCV) positive; Aortic Stenosis; coronaropathies; Pregnancy; Other genetic diseases; Neoplasms; Collagenopathies; Chemo/radiotherapy; Prolonged use of corticosteroids; Infections; Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV) (not vaccination) and Hepatitis C Virus (HCV) positive; Non end-stage heart failure; End Systolic Volume Index (ESVI)<35 ml/m2; Ejection Fraction (EF)>40%; Time from MI unknown; Pregnancy; Other genetic diseases; Neoplasms; Collagenopathies; Chemo/radiotherapy; Prolonged use of corticosteroids; Infections; Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV) (not vaccination) and Hepatitis C Virus (HCV) positive.

ClinicalTrials.gov NCT03268135